A NAT for reliable HBV DNA Screening of Plasma

  • Kang, Hye-Na (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Noh, Hyang-Soon (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Lee, Nam-Kyoung (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Kim, Soon-Nam (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Man, Hong-Choon (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Lee, Ki-Hong (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Oh, Ho-Jung (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Yoo, Si-Hyung (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Shin, In-Soo (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Choi, Seung-Eun (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Lee, Seok-Ho (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration) ;
  • Hong, Seung-Hwa (Blood Products Division, Boilogics Evaluation Department, Korea Food and Drug Administration)
  • Published : 2002.10.01

Abstract

The safety of blood and blood products is ensured by careful selection of donors. screening of donated blood and the use of validated viral inactivation and/or removal steps during the manufacture of blood products. Serologic screening procedures have substantially reduces the risk of transmission of blood-bone viruses. However, there are still residual risks despite these measures due to the inclusion of 'window period'donations. (omitted)

Keywords